Search
Tenax Therapeutics Inc
TENXAdd to Watchlist
15.460USD
+2.170+16.33%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
375.30MMarket Cap
LossP/E TTM
More Details of Tenax Therapeutics Inc Company
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).
Tenax Therapeutics Inc Info
Ticker SymbolTENX
Company nameTenax Therapeutics Inc
IPO dateOct 28, 1993
CEOGiordano (Christopher T)
Number of employees4
Security typeOrdinary Share
Fiscal year-endOct 28
Address101 Glen Lennox Drive
CityCHAPEL HILL
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code27517
Phone19198552100
Websitehttp://www.tenaxthera.com/
Ticker SymbolTENX
IPO dateOct 28, 1993
CEOGiordano (Christopher T)
Company Executives of Tenax Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Stuart Rich, M.D.
Dr. Stuart Rich, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
12.65K
+39.51%
Dr. Declan Doogan, M.D.
Dr. Declan Doogan, M.D.
Independent Director
Independent Director
2.27K
--
Mr. Gerald T. (Gerry) Proehl
Mr. Gerald T. (Gerry) Proehl
Independent Chairman of the Board
Independent Chairman of the Board
1.67K
--
Dr. June Almenoff, M.D., Ph.D.
Dr. June Almenoff, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Independent Director
Independent Director
--
--
Mr. Christopher T. (Chris) Giordano
Mr. Christopher T. (Chris) Giordano
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Robyn M. Hunter
Ms. Robyn M. Hunter
Independent Director
Independent Director
--
--
Mr. Thomas A. (Tom) Mcgauley
Mr. Thomas A. (Tom) Mcgauley
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Stuart Rich, M.D.
Dr. Stuart Rich, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
12.65K
+39.51%
Dr. Declan Doogan, M.D.
Dr. Declan Doogan, M.D.
Independent Director
Independent Director
2.27K
--
Mr. Gerald T. (Gerry) Proehl
Mr. Gerald T. (Gerry) Proehl
Independent Chairman of the Board
Independent Chairman of the Board
1.67K
--
Dr. June Almenoff, M.D., Ph.D.
Dr. June Almenoff, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Independent Director
Independent Director
--
--
Mr. Christopher T. (Chris) Giordano
Mr. Christopher T. (Chris) Giordano
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
FAQs
Who are the top five shareholders of Tenax Therapeutics Inc?
The top five shareholders of Tenax Therapeutics Inc are: Dr. Stuart Rich, M.D.
How many institutions hold shares of Tenax Therapeutics Inc (TENX)?
As of 2026Q1, 74 institutions hold shares of Tenax Therapeutics Inc, with a combined market value of approximately 11.71M, accounting for 51.15% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 5305648.00.